International Journal of Alzheimer's Disease

Volume 2012 (2012), Article ID 437025, 9 pages

doi:10.1155/2012/437025

Review Article

-Synuclein as CSF and Blood Biomarker of Dementia with Lewy Bodies

Kensaku Kasuga,1,2 Masatoyo Nishizawa,¹ and Takeshi Ikeuchi¹

¹Department of Neurology, Brain Research Institute, Niigata University, Niigata 951-8585, Japan

²Department of Neurosciences, University of California, San Diego, 9500 Gilman Drive, La Jolla, San Diego, CA 92093, USA

Received 8 June 2012; Revised 24 July 2012; Accepted 24 July 2012

Academic Editor: Walter Maetzler

Copyright © 2012 Kensaku Kasuga et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

Dementia with Lewy bodies (DLB) is a common subtype of dementia in the elderly. DLB is neuropathologically characterized by the presence of Lewy bodies and Lewy neurites, both of which are composed of α-synuclein. Although α-synuclein was initially considered to be an exclusively intracellular protein, it has been found to be secreted into biological fluids. α-Synuclein in biological fluids such as cerebrospinal fluid (CSF) and blood has been discussed as a potential biomarker of DLB and α-synuclein-related disorders, because α-synuclein is characteristically accumulated in the brain of patients with these disorders. The α-synuclein level in CSF has been examined by several investigators, and the majority of studies have shown a reduction in CSF α-synuclein level in DLB and α-synuclein-related disorders. Discrepant findings of studies of plasma α-synuclein level in patients with DLB have been reported. Because the level of α-synuclein stored in red blood cells is considerably high, blood contamination and haemolysis during sample collection and processing should be considered as a confounding factor for quantification of α-synuclein. Here, the recent progress in the studies of α-synuclein as a biomarker of DLB and their potential clinical applications are reviewed.

1. Introduction

Dementia with Lewy bodies (DLB) is a common subtype of dementia and is reported to be the second most common neurodegenerative dementia after Alzheimer’s disease (AD) in the elderly in several studies [1–3]. DLB is a progressive cognitive disorder characterized by fluctuating cognitive impairment, visual hallucination, and parkinsonism [4]. Diagnosis of DLB in patients with such characteristic clinical features would not be difficult by taking medical history and careful neurological examinations. However, it could be laborious to make an accurate diagnosis of DLB when patients have a substantial degree of concomitant AD pathology, which affects the clinical symptoms with lower rates of visual hallucinations and parkinsonism [5, 6]. Accurate clinical diagnosis of DLB is important because patients may benefit from cholinesterase inhibitors, which improve cognitive function and neuropsychiatric symptoms of DLB [7]. Furthermore, it should be noted that DLB patients are particularly sensitive to neuroleptic drugs [4, 8]. Recent intensive research has given hope for disease-modifying therapeutics for DLB to become a reality. The evaluation of such therapies largely depends on reliable diagnostic and prognostic biomarkers for early detection and monitoring of the stage of DLB. Candidates of such biomarkers are diverse; clinical biomarkers detected on the basis of olfactory function [9], myocardial ¹²³I-metaiodobenzylguanidine (MIBG) scintigraphy [10], neuroimaging biomarkers detected by magnetic resonance imaging (MRI), single photon emission computed tomography (SPECT) [11], positron emission tomography (PET), and biochemical biomarkers. In this paper, fluid biomarkers, particularly α-synuclein in cerebrospinal fluid (CSF) and blood in patients with DLB and α-synuclein-related disorders were extensively reviewed.

2. Lewy Bodies and α-Synuclein

A century ago, in 1912, Lewy originally described neuronal inclusions in the brain of patients with Parkinson’s disease (PD). Seven years later, a Russian neuropathologist, Tretiakoff, named the inclusions as “corps de Lewy (Lewy bodies)” [12]. Since the discovery, Lewy bodies have been considered as intracytoplasmic, spherical, and eosinophilic neuronal inclusions in the substantia nigra of PD patients. In 1976, Kosaka et al. reported the detection of Lewy bodies in the cerebral cortex of an elderly patient with dementia [13]. After his detailed description of cortical Lewy bodies [14], many similar cases were subsequently reported. Because the characteristic pathological features of DLB and PD are Lewy bodies and Lewy neurites, these disorders are considered to belong to a continuum disorder, and the generic term Lewy body disease (LBD) was proposed [4, 15].

In 1997, Spillantini et al. found that α-synuclein is the main component of Lewy bodies in the brains of PD and DLB patients [16]. Only two months before this report, a mutation was identified in SNCA, which encodes α-synuclein in families with autosomal dominant PD [17]. A different SNCA mutation was subsequently reported in a family with DLB [18]. In addition, SNCA multiplication by duplication/triplication has been identified in a large family with phenotypes ranging from DLB to PD [19]. These neuropathological and genetic findings suggest that α-synuclein is essentially implicated in the pathogenesis of LBD including DLB and PD. Recent studies have suggested that the Lewy body pathology propagates throughout the brain via neuron-to-neuron transmission of α-synuclein aggregates [20]. It has been demonstrated that glial cytoplasmic inclusions, which are unique pathological inclusions found in brains of patients with multiple system atrophy (MSA), are also composed of α-synuclein [21], suggesting an unexpected link between MSA and LBD. These disorders with pathological accumulation of α-synuclein in brains are termed as α-synucleinopathies [22].

α-Synuclein is a 140-residue ubiquitous protein and is highly expressed in neuronal presynaptic terminals under physiological conditions. Although its physiological functions remain unclear, α-synuclein is implicated in synaptic vesicle trafficking particularly in the regulation of synaptic vesicle release [23] and stabilization of SNARE complexes [24]. Deposited α-synuclein in the brain with synucleinopathies is aberrantly phosphorylated at Ser129 [25]. It has been demonstrated that the C-terminal truncated form of α-synuclein promotes the aggregation of α-synuclein [26]. Because α-synuclein has no signal sequence, it was initially considered to be an exclusively intracellular protein. However, it has been shown that α-synuclein is secreted into biological fluids [27, 28].

3. α-Synuclein in CSF

A year after Spillantini et al. reported that α-synuclein is the main component of Lewy bodies, Jakowec et al. examined whether α-synuclein is detectable in CSF [29]. They examined the expression of α-synuclein in CSF from PD patients and control subjects by Western blot analysis using an anti-α-synuclein specific antibody, but failed to detect α-synuclein in CSF [29]. Borghi et al. detected α-synuclein by a method combining immunoprecipitation with immunoblot analysis using two different anti-α-synuclein antibodies [30]. In their study, however, the intensity of the bands immunoreactive to the anti-α-synuclein antibodies showed no significant difference between patients with PD and control subjects [30]. El-Agnaf et al. also confirmed that α-synuclein is detectable in CSF by a similar methodology [27].

Subsequently, Tokuda et al. demonstrated using a new system for enzyme-linked immunosorbent assay (ELISA) that PD patients showed significantly lower α-synuclein levels in CSF than the control groups [31]. Since then, several studies to determine the total α-synuclein level in CSF have been carried out by ELISA or bead-based flow cytometric assay using various combinations of anti-α-synuclein antibodies (Tables 1 and 2). A significantly low level of α-synuclein in CSF from patients with LBD (PD and/or DLB) has been shown by independent studies [28, 31–38]. Our study revealed that total CSF α-synuclein level shows a significant positive correlation with the CSF Aβ42 level in DLB patients [32]. It has been suggested that a low CSF Aβ42 level may be related to amyloid-related pathology in the brains of DLB patients [39]. In addition, experimental studies have suggested that the Aβ42 species strongly enhances the accumulation of α-synuclein [40]. In the CSF from LBD patients, the level of Aβ42 shows a positive correlation with the activity of neprilysin, an enzyme that degrades Aβ [41]. Taken together, the reduction in α-synuclein and Aβ42 levels in CSF suggests the extent of Lewy body pathology and the co-occurrence of amyloid pathology, respectively, in the brain of DLB patients. Interestingly, patients with SNCA duplication who showed abundant Lewy body pathology in the brain [42] also show low levels of CSF α-synuclein [32]. Because the predominant source of α-synuclein in CSF is considered to be the central nervous system [43], the decrease in the level of CSF α-synuclein in DLB may reflect a dysfunction in the metabolism or clearance of α-synuclein in the brain, similarly to AD patients with Aβ accumulation in the brain showing a decrease in the level of Aβ42 in CSF.

Table 1: Studies on quantification of α-synuclein level in CSF of patients with DLB and other synucleinopathies.

Level of total α-synuclein
Study
      Blood contamination

was considered*
Controls

Synucleinopathies

Healthy controls
Neurological controls
AD
Lewy body diseases

Results

DLB
PD
MSA

Tokuda et al. [31]
No
9
29
—
—
33
—
PD patients showed significantly lower α-syn level than the controls (). The level of α-syn decreased significantly with age () and correlated to inversely assigned Hoehn and Yahr stage ().

Mollenhauer et al. [28]
No
—
13
13
38
8
—
The level of α-syn in DLB and PD patients were lower than AD patients and controls ().

Kasuga et al. [32]
No
—
21
31
34
—
—
The level of α-syn in DLB patients was significantly lower than those in patients with AD () and other dementias (). In DLB patients, reduced α-syn level correlated with the lower level of CSF Aβ42 (). Patients with SNCA duplication showed a decrease of CSF α-syn.

Tokuda et al. [44]
No
16
12
—
—
32
—
The level of total α-syn was lower in PD patients than in age-matched controls. The level of α-syn oligomers was significantly higher in PD patients than in age-matched controls.

Mollenhauer et al. [34]
Yes
—

—
76

20
62

3
55

66
51

273
29

15
Upper and lower rows indicate training and validation cohorts, respectively. The level of α-syn was significantly lower in DLB, PD, and MSA patients than in other neurological diseases.

Hong et al. [33]
Yes
92
—
38
—
86
20
The level of α-syn was decreased in PD and MSA patients.

Parnetti et al. [37]
Yes
—
32
48
32
38
—
The level of α-syn was lower in patients with neurodegenerative diseases than in cognitively normal subjects, but the level of α-syn alone did not distinguish synucleinopathies from tauopathies. An inverse correlation between α-syn and total tau levels was observed ().

Tateno et al. [36]
No
—
11
9
6
11
11
The levels of α-syn of DLB, PD, and MSA were lower than AD.

Wennstrom et al. [38]
No
24
—
26
18
—
—
The level of α-syn in female DLB patients was lower than AD () patients and controls ().

Öhrfeltet al. [45]
Yes
55
—
66
15
15
—
PD, DLB patients and controls showed comparable levels of α-syn. AD patients showed significantly lower level of α-syn than the controls (). AD patients with MMSE scores below 20 had significantly lower level of α-syn than AD patients with MMSE scores of 20 or higher ().

Noguchi-Shinohara et al. [46]
No
—
—
21
16
—
—
The level of α-syn did not differ between DLB and AD patients. In DLB patients, the duration of illness was associated with lower level of α-syn ().

Spies et al. [47]
No
57
—
131
40
—
—
The level of α-syn was comparable between DLB, AD, and controls. The level of α-syn decreased with age ().

Reesink et al. [48]
Yes
34
—
63
35
18
—
The level of α-syn was not different among PD, DLB, AD, and controls. In DLB patients, lower α-syn was related to lower MMSE scores () and worse category fluency ().

Aerts et al. [49]
Yes
57
—
—
3
58
47
The level of α-syn was comparable among PD, MSA, DLB patients and controls. In PD group, the level of α-syn was negatively correlated with age at time of lumber puncture ().

Foulds et al. [50]
Yes
20
—
—
16
38
8
The level of total α-syn was not different between PD, DLB, MSA and control groups. Oligomeric phosphorylated α-syn was significantly high in patients with MSA ().

Park et al. [51]
No
18
11
—
—
23
—
The level of total α-syn in PD patients was comparable to that of control groups. The level of α-syn oligomer in PD patients was significantly higher than controls ().

Arrows indicate decreased (↓) and comparable (→) levels α-synuclein. Sample numbers are shown in each category. *Erythrocyte counts or haemoglobin levels were considered as a confounding factor. AD: Alzheimer’s disease; DLB: dementia with Lewy bodies; PD: Parkinson’s disease; MSA: multiple system atrophy; α-syn: α-synuclein; MMSE: minimental state examination.

Table 2: Summary of antibodies used to quantify α-synuclein in biofluids.

Study
Target molecule
Anti-α-synuclein antibodies

Capture antibody
Detecting antibody

Tokuda et al. [31]
Total α-synuclein
211 (m)
FL-140 (p)

Mollenhouer et al. [28]
Total α-synuclein
mSA-1 (p)
Syn-1 (m)

Öhrfeltet al. [45]
Total α-synuclein
Syn1b (m)
Syn3b (m), Syn5d (m)

Noguchi-Shinohara et al. [46]
Total α-synuclein
211 (m)
FL-140 (p)

Spies et al. [52]
Total α-synuclein
211 (m)
FL-140 (p)

Kasuga et al. [32]
Total α-synuclein
Syn-1 (m)
FL-140 (p)

Reesink et al. [48]
Total α-synuclein
211 (m)
FL-140 (p)

Tokuda et al. [44]
Total α-synuclein
211 (m)
FL-140 (p)

Oligomeric α-synuclein
211 (m)
Biotinylated 211 (m)

Aerts et al. [49]
Total α-synuclein
211 (m)
FL-140 (p)

Mollenhouer et al. [34]
Total α-synuclein
mSA-1 (p)
Syn-1 (m)

Hong et al. [33]
Total α-synuclein
211 (m), LB509 (m), rabbit anti-α-synuclein (p)
Biotinylated goat anti-human α-synuclein (p)

Parnetti et al. [37]
Total α-synuclein
211 (m)
FL-140 (p)

Foulds et al.[50]
Total α-synuclein
211 (m)
FL-140 (p)

Oligomeric α-synuclein
211 (m)
Biotinylated 211 (m)

Phosphorylated α-synuclein
N-19 (p)
pS129 (m)

Oligomeric phosphorylated α-synuclein
pS129 (m)
Biotinylated pS129 (m)

Tateno et al. [36]
Total α-synuclein
Not described
Not described

Wennstrom et al. [38]
Total α-synuclein
Commercial kit (Invitrogen)

Park et al. [51]
Total α-synuclein
211 (m)
FL-140 (p)

Oligomeric α-synuclein
211 (m)
Biotinylated 211 (m)

m: monoclonal antibody; p: polyclonal antibody.

In contrast, comparable levels of total α-synuclein in CSF between patients with LBD and control subjects have also been reported [45–50]. This discrepancy is probably not due to the misdiagnosis of LBD, because different studies using CSF samples derived from autopsy-confirmed patients showed significantly decreased or comparable α-synuclein levels in LBD patients [34, 50]. In addition to methodological differences in the quantification of α-synuclein, blood contamination of CSF during lumbar puncture should be taken into account when considering the discrepant results. The level of α-synuclein in blood, particularly that stored in red blood cells, is much higher than that in CSF [33, 53]. Haemolysis in the course of sample collection and processing should be considered as a confounding factor for quantification of α-synuclein level in CSF and blood. Other factors such as level fluctuations over time and drug treatment may have less effect on the level of α-synuclein in CSF. Although the level of Aβ in CSF fluctuates over time [54], the level of α-synuclein in CSF does not significantly change [52]. It is also reported that drugs such as L-dopa and dopamine agonists do not affect the level of α-synuclein in CSF [34, 35].

Several groups have recently conducted studies to detect the oligomeric forms of α-synuclein in CSF, because the oligomer species of α-synuclein are considered to be toxic and could enhance pathological accumulation of α-synuclein and disease propagation [55]. Tokuda et al. demonstrated that the levels of α-synuclein oligomers in CSF are significantly higher in patients with PD than in patients with progressive supranuclear palsy (PSP) or AD [44]. In their study, the level of total α-synuclein in the CSF from PD patients tends to decrease [44]. Increased level of α-synuclein oligomers in CSF from PD patients was also shown by other investigator [51]. Foulds et al. showed that the level of oligomers composed of phosphorylated α-synuclein is higher in the postmortem CSF from MSA patients than in that from with PD, DLB, or PSP patients [50]. Sierks et al. also showed a significant increase in the level of α-synuclein oligomers in postmortem CSF from patients with PD by electrochemical impedance spectroscopy [56]. These findings suggest a possibility that α-synuclein oligomer species are detectable in CSF and that their levels may increase in some patients with synucleinopathies. A potential concern is that the oligomeric forms of α-synuclein detected in their studies using different methods may be heterogeneous in size and toxicity; hence, further validation is still needed.

Correlation analysis of clinical parameters, such as minimental state examination (MMSE) and Hoehn Yahr scale scores with the total α-synuclein level in CSF, has shown inconsistent results. Tokuda et al. showed an inverse correlation between the total α-synuclein level in CSF and disease severity determined by the Hoehn Yahr scale [31]. A low α-synuclein level was reported to correlate with a low MMSE score of DLB patients [48]. These findings suggest that α-synuclein level in CSF may reflect the severity of pathological changes occurring in patients with LBD. This notion is supported by the findings of a study that the disease duration in patients with DLB is closely associated with a low α-synuclein level in CSF [46]. In contrast to these findings, other studies revealed no significant association of the α-synuclein level in CSF with MMSE score, gender, age at examination, or disease duration in DLB or AD patients [32]. Shi et al. examined whether CSF α-synuclein level correlates with dopaminergic dysfunction determined by PET in asymptomatic carriers with leucine-rich repeat kinase 2 (LRRK2) gene mutation [64]. They detected no significant correlations, indicating that CSF total α-synuclein level may not be a sensitive biomarker of the preclinical phase of PD.

4. α-Synuclein in Blood

Several studies on the quantification of α-synuclein in blood have been carried out because drawing blood is much less invasive than lumbar puncture to obtain CSF from patients (Table 3). El-Agnaf et al. detected α-synuclein in plasma of patients with LBD by immunoprecipitation using an anti-α-synuclein antibody [27]. Subsequently, they found higher levels of α-synuclein oligomers in plasma from PD patients than in that from control subjects by ELISA [57]. A similar increase in α-synuclein level was observed in plasma from patients with PD and MSA [58, 59]. Lee et al. found that plasma α-synuclein level is higher in patients with PD than in those with MSA [58]. Duran et al. demonstrated that drugs such as L-dopa, dopamine agonists, and MAO/COMT inhibitors do not affect the plasma α-synuclein level in patients with PD [59]. The phosphorylated α-synuclein level in plasma quantified by ELISA as well as Western blot analysis is higher in patients with PD than in control subjects [60]. In their study, the level of α-synuclein remained stable within the same individuals at least over 3 months.

Table 3: Studies of quantification of α-synuclein level in blood of patients with DLB and other synucleinopathies.

Methods
Samples*
Results**

El-Agnaf et al. [57]
ELISA
Plasma

Cont (27), PD/DLB (34)
α-Synuclein oligomers were elevated in patients with PD/DLB compared to controls.

Lee et al. [58]
ELISA
Plasma

Cont (51), PD (105), MSA (38)
The α-synuclein level was increased in patients with PD (79.9 pg/mL) and in those with MSA (78.1 pg/mL) compared with controls (76.1 pg/mL). The α-synuclein level was significantly higher in patients with PD than in those with MSA.

Duran et al. [59]
ELISA
Plasma

Cont (60), PD (95)
The α-synuclein level was elevated in patients with PD compared to healthy controls. Antiparkinsonian treatment does not change plasma α-synuclein level.

Foulds et al. [60]
ELISA
Plasma

(not described)
The level of phosphorylated α-synuclein was higher in patients with PD than healthy controls. None of the levels of total α-synuclein, oligomeric α-synuclein, or oligomeric phospohorylated α-synuclein was different between PD patients and controls.

Shi et al. [61]
Bead-based flow cytometric assay
Plasma

Cont (95), AD (33), PD (117)
No significant difference was found among patients with PD (36.8 ng/mL), AD (32.4 ng/mL), and those with healthy controls (39.5 ng/mL).

Park et al. [51]
ELISA
Plasma

Cont (29), PD(23)
There was no difference in oligomeric and total α-synuclein in plasma between PD patients and controls.

Li et al. [62]
IP-Western blot
Plasma

Cont (11), PD (27)
The α-synuclein level was significantly lower in patients with PD than in those with age-matched healthy controls. Early-onset PD patients had lower α-synuclein levels than late-onset PD patients.

Laske et al. [63]
ELISA
Serum

Cont (40), AD (80), DLB (40)
The α-synuclein level was significantly lower in patients with DLB (4.7 ng/mL) than in those with AD (7.0 ng/mL) and healthy controls (8.1 ng/mL).

Arrows indicate increased (↑), comparable (→), and decreased (↓) levels of α-synuclein.*Sample numbers are shown in parenthesis. **Values are indicated as mean or median. AD: Alzheimer’s disease; Cont: controls; DLB: dementia with Lewy bodies; IP: immunoprecipitation; MSA: multiple system atrophy; PD: Parkinson’s disease.

By contrast, Li et al. found a significantly decreased α-synuclein level in plasma from patients with PD by Western blot analysis, which detected only full-length monomeric α-synuclein [62]. Laske et al. also reported a similar decrease in serum α-synuclein level in DLB patients compared with AD patients and control subjects [63]. Comparable levels of plasma α-synuclein were found among patients with PD, AD, and control subjects in other studies [61].

5. Conclusions

Results of measurements of α-synuclein level in CSF and blood have been variable; hence, it is difficult to unequivocally conclude whether α-synuclein is a promising fluid biomarker of DLB and other α-synucleinopathies. More discriminating results for DLB patients could be obtained by examining specific α-synuclein species such as truncated, phosphorylated, and oligomeric species on the basis of their analogy to Aβ42 and phosphorylated tau species whose changes in levels are found to be reliable CSF biomarkers of AD. In addition, a multicenter study is required to validate the usefulness of α-synuclein as a biomarker by standardized methods of quantifying α-synuclein. Continuous efforts will be required to establish useful fluid biomarkers for early diagnosis of DLB and evaluation of disease-modifying therapeutics for DLB.

Acknowledgments

The authors would like to thank Drs. Takayoshi Tokutake, Atsushi Ishikawa, and Osamu Onodera for their helpful discussion on this paper.

References

Y. Matsui, Y. Tanizaki, H. Arima et al., “Incidence and survival of dementia in a general population of Japanese elderly: the hisayama study,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 80, no. 4, pp. 366–370, 2009.

T. Rahkonen, U. Eloniemi-Sulkava, S. Rissanen, A. Vatanen, P. Viramo, and R. Sulkava, “Dementia with Lewy bodies according to the consensus criteria in a general population aged 75 years or older,” Journal of Neurology Neurosurgery and Psychiatry, vol. 74, no. 6, pp. 720–724, 2003.

D. Aarsland, A. Rongve, S. Piepenstock Nore et al., “Frequency and case identification of dementia with Lewy bodies using the revised consensus criteria,” Dementia and Geriatric Cognitive Disorders, vol. 26, no. 5, pp. 445–452, 2008.

I. G. McKeith, D. Galasko, K. Kosaka et al., “Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop,” Neurology, vol. 47, no. 5, pp. 1113–1124, 1996.

I. G. McKeith, D. W. Dickson, J. Lowe, et al., “Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium,” Neurology, vol. 65, no. 12, pp. 1863–1872, 2005.

A. R. Merdes, L. A. Hansen, D. V. Jeste et al., “Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies,” Neurology, vol. 60, no. 10, pp. 1586–1590, 2003.

J. T. O'Brien and A. Burns, “Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology,” Journal of Psychopharmacology, vol. 25, no. 8, pp. 997–1019, 2011.

D. Aarsland, R. Perry, J. P. Larsen et al., “Neuroleptic sensitivity in Parkinson's disease and Parkinsonian dementias,” Journal of Clinical Psychiatry, vol. 66, no. 5, pp. 633–637, 2005.

A. Haehner, T. Hummel, and H. Reichmann, “Olfactory dysfunction as a diagnostic marker for Parkinson's disease,” Expert Review of Neurotherapeutics, vol. 9, no. 12, pp. 1773–1779, 2009.

S. Orimo, M. Suzuki, A. Inaba, et al., “(123)I-MIBG myocardial scintigraphy for differentiating Parkinson's disease from other neurodegenerative parkinsonism: a systematic review and meta-analysis,” Parkinsonism and Related Disorders, vol. 18, no. 5, pp. 494–500, 2012.

I. McKeith, J. O'Brien, Z. Walker et al., “Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study,” The Lancet Neurology, vol. 6, no. 4, pp. 305–313, 2007.

A. M. Rodrigues E Silva, F. Geldsetzer, B. Holdorff et al., “Who was the man who discovered the “Lewy bodies”?” Movement Disorders, vol. 25, no. 12, pp. 1765–1773, 2010.

K. Kosaka, S. Oyanagi, and M. Matsushita, “Presenile dementia with Alzheimer, Pick and Lewy body changes,” Acta Neuropathologica, vol. 36, no. 3, pp. 221–233, 1976.

K. Kosaka, “Lewy bodies in cerebral cortex. Report of three cases,” Acta Neuropathologica, vol. 42, no. 2, pp. 127–134, 1978.

C. F. Lippa, J. E. Duda, M. Grossman et al., “DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers,” Neurology, vol. 68, no. 11, pp. 812–819, 2007.

M. G. Spillantini, M. L. Schmidt, V. M. Y. Lee, J. Q. Trojanowski, R. Jakes, and M. Goedert, “α-synuclein in Lewy bodies,” Nature, vol. 388, no. 6645, pp. 839–840, 1997.

M. H. Polymeropoulos, C. Lavedan, E. Leroy et al., “Mutation in the α-synuclein gene identified in families with Parkinson's disease,” Science, vol. 276, no. 5321, pp. 2045–2047, 1997.

J. J. Zarranz, J. Alegre, J. C. Gómez-Esteban et al., “The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia,” Annals of Neurology, vol. 55, no. 2, pp. 164–173, 2004.

A. B. Singleton, M. Farrer, J. Johnson et al., “α-synuclein locus triplication causes Parkinson's disease,” Science, vol. 302, no. 5646, p. 841, 2003.

P. Desplats, H. J. Lee, E. J. Bae et al., “Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 31, pp. 13010–13015, 2009.

K. Wakabayashi, M. Yoshimoto, S. Tsuji, and H. Takahashi, “α-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy,” Neuroscience Letters, vol. 249, no. 2-3, pp. 180–182, 1998.

M. G. Spillantini and M. Goedert, “The α-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy,” Annals of the New York Academy of Sciences, vol. 920, pp. 16–27, 2000.

A. Abeliovich, Y. Schmitz, I. Fariñas et al., “Mice lacking α-synuclein display functional deficits in the nigrostriatal dopamine system,” Neuron, vol. 25, no. 1, pp. 239–252, 2000.

J. Burré, M. Sharma, T. Tsetsenis, V. Buchman, M. R. Etherton, and T. C. Südhof, “α-synuclein promotes SNARE-complex assembly in vivo and in vitro,” Science, vol. 329, no. 5999, pp. 1663–1667, 2010.

H. Fujiwara, M. Hasegawa, N. Dohmae et al., “α-synuclein is phosphorylated in synucleinopathy lesions,” Nature Cell Biology, vol. 4, no. 2, pp. 160–164, 2002.

W. Li, N. West, E. Colla et al., “Aggregation promoting C-terminal truncation of α-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 6, pp. 2162–2167, 2005.

O. M. El-Agnaf, S. A. Salem, K. E. Paleologou, et al., “Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma,” The FASEB Journal, vol. 17, no. 13, pp. 1945–1947, 2003.

B. Mollenhauer, V. Cullen, I. Kahn et al., “Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration,” Experimental Neurology, vol. 213, no. 2, pp. 315–325, 2008.

M. W. Jakowec, G. M. Petzinger, S. Sastry, D. M. Donaldson, A. McCormack, and J. W. Langston, “The native form of α-synuclein is not found in the cerebrospinal fluid of patients with Parkinson's disease or normal controls,” Neuroscience Letters, vol. 253, no. 1, pp. 13–16, 1998.

R. Borghi, R. Marchese, A. Negro et al., “Full length α-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects,” Neuroscience Letters, vol. 287, no. 1, pp. 65–67, 2000.

T. Tokuda, S. A. Salem, D. Allsop et al., “Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease,” Biochemical and Biophysical Research Communications, vol. 349, no. 1, pp. 162–166, 2006.

K. Kasuga, T. Tokutake, A. Ishikawa et al., “Differential levels of α-synuclein, β-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 81, no. 6, pp. 608–610, 2010.

Z. Hong, M. Shi, K. A. Chung et al., “DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease,” Brain, vol. 133, pp. 713–726, 2010.

B. Mollenhauer, J. J. Locascio, W. Schulz-Schaeffer, F. Sixel-Döring, C. Trenkwalder, and M. G. Schlossmacher, “α-synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study,” The Lancet Neurology, vol. 10, no. 3, pp. 230–240, 2011.

M. Shi, J. Bradner, A. M. Hancock et al., “Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression,” Annals of Neurology, vol. 69, no. 3, pp. 570–580, 2011.

F. Tateno, R. Sakakibara, T. Kawai, et al., “Alpha-synuclein in the cerebrospinal fluid differentiates synucleinopathies (Parkinson disease, dementia with lewy bodies, multiple system atrophy) from Alzheimer disease,” Alzheimer Disease and Associated Disorders, vol. 26, no. 3, pp. 213–216, 2012.

L. Parnetti, D. Chiasserini, G. Bellomo et al., “Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias,” Movement Disorders, vol. 26, no. 8, pp. 1428–1435, 2011.

M. Wennstrom, E. Londos, L. Minthon, et al., “Altered CSF orexin and alpha-synuclein levels in dementia patients,” Journal of Alzheimer's Disease, vol. 29, no. 1, pp. 125–132, 2012.

D. Strozyk, K. Blennow, L. R. White, and L. J. Launer, “CSF Aß 42 levels correlate with amyloid-neuropathology in a population-based autopsy study,” Neurology, vol. 60, no. 4, pp. 652–656, 2003.

O. Pletnikova, N. West, M. K. Lee et al., “Aβ deposition is associated with enhanced cortical α-synuclein lesions in Lewy body diseases,” Neurobiology of Aging, vol. 26, no. 8, pp. 1183–1192, 2005.

W. Maetzler, V. Stoycheva, B. Schmid et al., “Neprilysin activity in cerebrospinal fluid is associated with dementia and amyloid-β42 levels in lewy body disease,” Journal of Alzheimer's Disease, vol. 22, no. 3, pp. 933–938, 2010.

T. Ikeuchi, A. Kakita, A. Shiga et al., “Patients homozygous and heterozygous for SNCA duplication in a family with parkinsonism and dementia,” Archives of Neurology, vol. 65, no. 4, pp. 514–519, 2008.

B. Mollenhauer, E. Trautmann, B. Otte, et al., “Alpha-synuclein in human cerebrospinal fluid is principally derived from neurons of the central nervous system,” Journal of Neural Transmission, vol. 119, no. 7, pp. 739–746, 2012.

T. Tokuda, M. M. Qureshi, M. T. Ardah et al., “Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease,” Neurology, vol. 75, no. 20, pp. 1766–1772, 2010.

A. Öhrfelt, P. Grognet, N. Andreasen et al., “Cerebrospinal fluid α-synuclein in neurodegenerative disorders—a marker of synapse loss?” Neuroscience Letters, vol. 450, no. 3, pp. 332–335, 2009.

M. Noguchi-Shinohara, T. Tokuda, M. Yoshita et al., “CSF α-synuclein levels in dementia with Lewy bodies and Alzheimer's disease,” Brain Research, vol. 1251, pp. 1–6, 2009.

P. E. Spies, R. J. F. Melis, M. J. C. Sjögren, M. G. M. O. Rikkert, and M. M. Verbeek, “Cerebrospinal fluid α-synuclein does not discriminate between dementia disorders,” Journal of Alzheimer's Disease, vol. 16, no. 2, pp. 363–369, 2009.

F. E. Reesink, A. W. Lemstra, K. D. van Dijk et al., “CSF α-synuclein does not discriminate dementia with Lewy bodies from Alzheimer's disease,” Journal of Alzheimer's Disease, vol. 22, no. 1, pp. 87–95, 2010.

M. B. Aerts, R. A. J. Esselink, W. F. Abdo, B. R. Bloem, and M. M. Verbeek, “CSF α-synuclein does not differentiate between parkinsonian disorders,” Neurobiology of Aging, vol. 33, no. 2, pp. 431–433, 2012.

P. G. Foulds, O. Yokota, A. Thurston, et al., “Post mortem cerebrospinal fluid alpha-synuclein levels are raised in multiple system atrophy and distinguish this from the other alpha-synucleinopathies, Parkinson's disease and dementia with Lewy bodies,” Neurobiology of Disease, vol. 45, no. 1, pp. 188–195, 2012.

M. J. Park, S. M. Cheon, H. R. Bae, et al., “Elevated levels of alpha-synuclein oligomer in the cerebrospinal fluid of drug-naive patients with Parkinson's disease,” Journal of Clinical Neurology, vol. 7, no. 4, pp. 215–222, 2011.

P. E. Spies, D. Slats, M. G. Rikkert, et al., “CSF alpha-synuclein concentrations do not fluctuate over hours and are not correlated to amyloid beta in humans,” Neuroscience Letters, vol. 504, no. 3, pp. 336–338, 2011.

R. Barbour, K. Kling, J. P. Anderson et al., “Red blood cells are the major source of alpha-synuclein in blood,” Neurodegenerative Diseases, vol. 5, no. 2, pp. 55–59, 2008.

R. J. Bateman, G. Wen, J. C. Morris, and D. M. Holtzman, “Fluctuations of CSF amyloid-β levels: implications for a diagnostic and therapeutic biomarker,” Neurology, vol. 68, no. 9, pp. 666–669, 2007.

K. Vekrellis, M. Xilouri, E. Emmanouilidou, et al., “Pathological roles of alpha-synuclein in neurological disorders,” The Lancet Neurology, vol. 10, no. 11, pp. 1015–1025, 2011.

M. R. Sierks, G. Chatterjee, C. McGraw, et al., “CSF levels of oligomeric alpha-synuclein and beta-amyloid as biomarkers for neurodegenerative disease,” Integrative Biology, vol. 3, no. 12, pp. 1188–1196, 2011.

O. M. A. El-Agnaf, S. A. Salem, K. E. Paleologou et al., “Detection of oligomeric forms of α-synuclein protein in human plasma as a potential biomarker for Parkinson's disease,” The FASEB Journal, vol. 20, no. 3, pp. 419–425, 2006.

P. H. Lee, G. Lee, H. J. Park, O. Y. Bang, I. S. Joo, and K. Huh, “The plasma alpha-synuclein levels in patients with Parkinson's disease and multiple system atrophy,” Journal of Neural Transmission, vol. 113, no. 10, pp. 1435–1439, 2006.

R. Duran, F. J. Barrero, B. Morales, J. D. Luna, M. Ramirez, and F. Vives, “Plasma α-synuclein in patients with Parkinson's disease with and without treatment,” Movement Disorders, vol. 25, no. 4, pp. 489–493, 2010.

P. G. Foulds, J. D. Mitchell, A. Parker, et al., “Phosphorylated alpha-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson's disease,” The FASEB Journal, vol. 25, no. 12, pp. 4127–4137, 2011.

M. Shi, C. P. Zabetian, A. M. Hancock et al., “Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease,” Neuroscience Letters, vol. 480, no. 1, pp. 78–82, 2010.

Q. X. Li, S. S. Mok, K. M. Laughton et al., “Plasma α-synuclein is decreased in subjects with Parkinson's disease,” Experimental Neurology, vol. 204, no. 2, pp. 583–588, 2007.

C. Laske, A. J. Fallgatter, E. Stransky, K. Hagen, D. Berg, and W. Maetzler, “Decreased alpha-synuclein serum levels in patients with Lewy body dementia compared to Alzheimer's disease patients and control subjects,” Dementia and Geriatric Cognitive Disorders, vol. 31, no. 6, pp. 413–416, 2011.

M. Shi, A. R. Furay, V. Sossi, et al., “DJ-1 and alphaSYN in LRRK2 CSF do not correlate with striatal dopaminergic function,” Neurobiology of Aging, vol. 33, no. 4, pp. 836.e5–836.e7, 2012.